The application of MRD dynamic monitoring in the efficacy evaluation of TACE combined with targeted immunotherapy for liver cancer

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2200058596

Enrollment

Unknown

Registered

2022-04-12

Start date

2022-05-01

Completion date

Unknown

Last updated

2024-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liver Cancer

Interventions

Experimental group:TACE in combination with targeted immunotherapy

Eligibility

Sex/Gender

All

Age

18 Years to 110 Years

Inclusion criteria

Inclusion criteria: 1. Aged >=18 years; 2. No gender limit; 3. Patients with liver cancer confirmed by pathology; 4. Liver cancer patients receiving TACE combined with targeted immunotherapy; 5. Subjects voluntarily participate in the study and sign the informed consent.

Exclusion criteria

Exclusion criteria: 1. Insufficient tissue samples can be obtained for NGS detection; 2. Contraindications for TACE treatment; 3. Clinical information needed for research cannot be obtained; 4. Failure to cooperate with or agree to follow-up visits.

Design outcomes

Primary

Measure	Time frame
Tumor progression;	—

Secondary

Measure	Time frame
Minimal residual lesion (MRD) positive;	—

Countries

China

Contacts

Public ContactXie Hui

xh302r@126.com+86 13391507655

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026